AR092086A1 - Composicion con factores de crecimiento destinada al tratamiento intranasal de una enfermedad neurodegenerativa u otra patologia del sistema nervioso central, y su metodo de fabricacion - Google Patents
Composicion con factores de crecimiento destinada al tratamiento intranasal de una enfermedad neurodegenerativa u otra patologia del sistema nervioso central, y su metodo de fabricacionInfo
- Publication number
- AR092086A1 AR092086A1 ARP130102835A ARP130102835A AR092086A1 AR 092086 A1 AR092086 A1 AR 092086A1 AR P130102835 A ARP130102835 A AR P130102835A AR P130102835 A ARP130102835 A AR P130102835A AR 092086 A1 AR092086 A1 AR 092086A1
- Authority
- AR
- Argentina
- Prior art keywords
- growth factors
- composition
- nervous system
- central nervous
- pathology
- Prior art date
Links
- 239000003102 growth factor Substances 0.000 title abstract 7
- 239000000203 mixture Substances 0.000 title abstract 7
- 210000003169 central nervous system Anatomy 0.000 title abstract 4
- 230000004770 neurodegeneration Effects 0.000 title abstract 4
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 4
- 230000007170 pathology Effects 0.000 title abstract 4
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000008280 blood Substances 0.000 abstract 5
- 210000004369 blood Anatomy 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 5
- 239000000126 substance Substances 0.000 abstract 3
- 230000001225 therapeutic effect Effects 0.000 abstract 3
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/19—Platelets; Megacaryocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Otolaryngology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201200810A ES2442242B1 (es) | 2012-08-09 | 2012-08-09 | Composición con factores de crecimiento destinada al tratamiento intranasal de una enfermedad neurodegenerativa u otra patología del sistema nervioso central, y su método de fabricación. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR092086A1 true AR092086A1 (es) | 2015-03-25 |
Family
ID=49111229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130102835A AR092086A1 (es) | 2012-08-09 | 2013-08-08 | Composicion con factores de crecimiento destinada al tratamiento intranasal de una enfermedad neurodegenerativa u otra patologia del sistema nervioso central, y su metodo de fabricacion |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20140044795A1 (enExample) |
| EP (1) | EP2883569B1 (enExample) |
| JP (1) | JP6339568B2 (enExample) |
| KR (1) | KR102149162B1 (enExample) |
| CN (1) | CN104519961A (enExample) |
| AR (1) | AR092086A1 (enExample) |
| BR (1) | BR112015002760A2 (enExample) |
| CA (1) | CA2881075A1 (enExample) |
| CL (1) | CL2014003510A1 (enExample) |
| CO (1) | CO7170177A2 (enExample) |
| ES (2) | ES2442242B1 (enExample) |
| IN (1) | IN2014MN02675A (enExample) |
| MX (1) | MX357828B (enExample) |
| PE (1) | PE20150616A1 (enExample) |
| RU (1) | RU2696497C2 (enExample) |
| TW (1) | TWI649084B (enExample) |
| WO (1) | WO2014023860A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CL2016003282A1 (es) | 2016-12-21 | 2017-08-18 | Univ Chile | Virus aav/igf2, método de tratamiento genético y su uso en enfermedades relacionadas con mal plegamiento de proteínas tal como la enfermedad de huntington |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2049500A (en) * | 1998-12-09 | 2000-06-26 | Chiron Corporation | Administration of neurotrophic agents to the central nervous system |
| AR022333A1 (es) | 1999-01-26 | 2002-09-04 | Anitua Aldecoa Eduardo | Regenerador de tejido oseo |
| US6811777B2 (en) * | 2002-04-13 | 2004-11-02 | Allan Mishra | Compositions and minimally invasive methods for treating incomplete connective tissue repair |
| US7608258B2 (en) * | 2002-04-13 | 2009-10-27 | Allan Mishra | Method for treatment of tendinosis using platelet rich plasma |
| ES2221770B2 (es) | 2002-04-19 | 2006-07-16 | Eduardo Anitua Aldecoa | Metodo de preparacion de un compuesto para la regeneracion de tejidos. |
| US20060004189A1 (en) * | 2004-07-02 | 2006-01-05 | James Gandy | Compositions for treating wounds and processes for their preparation |
| US20070054843A1 (en) * | 2005-08-26 | 2007-03-08 | Yeomans David C | Methods for treatment of headaches by administration of oxytocin |
| WO2008154337A1 (en) * | 2007-06-08 | 2008-12-18 | Healthpartners Research Foundation | Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to the central nervous system |
| ES2333498B1 (es) * | 2007-08-02 | 2011-01-10 | Biotechnology Institute, I Mas D, S.L. | Metodo y compuesto para el tratamiento de enfermedades o dolencias articulares o para el tratamiento de la piel con fines esteticos u otros, y el metodo de preparacion del compuesto. |
| KR20100075493A (ko) * | 2007-09-14 | 2010-07-02 | 에스씨아이엘 테크놀로지 게엠베하 | 퇴행성 질환의 치료를 위한 신경내분비 인자 |
| TWI571275B (zh) * | 2009-05-14 | 2017-02-21 | 生物技術研究公司 | 從血液製備至少一種化合物之方法、及用於實施該方法之萃取裝置 |
| KR101114712B1 (ko) * | 2009-10-23 | 2012-02-29 | 세원셀론텍(주) | 염화칼슘용액과 제1형 콜라겐으로 혈소판풍부혈장(ｐｒｐ)을 활성화하여 조직재생을 유도하는 조성물의 제조방법 |
| ES2369945B1 (es) * | 2011-07-29 | 2012-10-15 | Eduardo Anitua Aldecoa | Procedimiento de obtención de una composición que contiene factores de crecimiento a partir de un compuesto sanguíneo, y composición obtenible por dicho procedimiento. |
-
2012
- 2012-08-09 ES ES201200810A patent/ES2442242B1/es not_active Expired - Fee Related
-
2013
- 2013-07-19 WO PCT/ES2013/000176 patent/WO2014023860A1/es not_active Ceased
- 2013-07-19 TW TW102125858A patent/TWI649084B/zh not_active IP Right Cessation
- 2013-07-19 CN CN201380041280.4A patent/CN104519961A/zh active Pending
- 2013-07-19 ES ES13756518.0T patent/ES2662385T3/es active Active
- 2013-07-19 CA CA2881075A patent/CA2881075A1/en not_active Abandoned
- 2013-07-19 BR BR112015002760A patent/BR112015002760A2/pt not_active Application Discontinuation
- 2013-07-19 EP EP13756518.0A patent/EP2883569B1/en not_active Not-in-force
- 2013-07-19 RU RU2015104076A patent/RU2696497C2/ru active
- 2013-07-19 JP JP2015525915A patent/JP6339568B2/ja not_active Expired - Fee Related
- 2013-07-19 MX MX2015001677A patent/MX357828B/es active IP Right Grant
- 2013-07-19 PE PE2015000116A patent/PE20150616A1/es not_active Application Discontinuation
- 2013-07-19 KR KR1020157001551A patent/KR102149162B1/ko not_active Expired - Fee Related
- 2013-08-08 US US13/962,340 patent/US20140044795A1/en not_active Abandoned
- 2013-08-08 AR ARP130102835A patent/AR092086A1/es unknown
-
2014
- 2014-12-23 CL CL2014003510A patent/CL2014003510A1/es unknown
- 2014-12-31 IN IN2675MUN2014 patent/IN2014MN02675A/en unknown
-
2015
- 2015-01-20 CO CO15010369A patent/CO7170177A2/es unknown
-
2016
- 2016-03-08 US US15/063,969 patent/US20160184360A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150040860A (ko) | 2015-04-15 |
| IN2014MN02675A (enExample) | 2015-08-28 |
| US20160184360A1 (en) | 2016-06-30 |
| EP2883569B1 (en) | 2017-12-20 |
| RU2696497C2 (ru) | 2019-08-02 |
| CL2014003510A1 (es) | 2015-05-04 |
| EP2883569A1 (en) | 2015-06-17 |
| US20140044795A1 (en) | 2014-02-13 |
| MX357828B (es) | 2018-07-25 |
| JP6339568B2 (ja) | 2018-06-06 |
| KR102149162B1 (ko) | 2020-08-31 |
| ES2442242A1 (es) | 2014-02-10 |
| ES2442242B1 (es) | 2014-11-25 |
| JP2015524464A (ja) | 2015-08-24 |
| TW201408310A (zh) | 2014-03-01 |
| BR112015002760A2 (pt) | 2020-04-22 |
| PE20150616A1 (es) | 2015-05-25 |
| TWI649084B (zh) | 2019-02-01 |
| CA2881075A1 (en) | 2014-02-13 |
| RU2015104076A (ru) | 2016-09-27 |
| CN104519961A (zh) | 2015-04-15 |
| WO2014023860A1 (es) | 2014-02-13 |
| CO7170177A2 (es) | 2015-01-28 |
| ES2662385T3 (es) | 2018-04-06 |
| MX2015001677A (es) | 2015-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2012003722A1 (es) | Compuestos derivados del acido naf-2-ilacetico; composicion farmaceutica; y uso para el tratamiento del sida. | |
| RU2018145985A (ru) | Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений | |
| CL2014000630A1 (es) | Una composicion que comprende 1) un compuesto derivado de nucleosido denominado como compuesto 10 y 2) un compuesto derivado de acido 5-tiofeno-2-carboxilico denominado como compuesto 5 o un compuesto derivado del ester metilico del acido carbamico denominado como compuesto 6; y su uso para el tratamiento profilactico o terapeutico de una infeccion por vhc. | |
| BR112014010206A2 (pt) | composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença | |
| BR112014010177A2 (pt) | composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença | |
| PT2935303T (pt) | 4'-fluoro-nucleósidos, 4'-fluoro-nucleótidos e seus análogos para o tratamento de hcv | |
| CL2013003372A1 (es) | Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes. | |
| MX375417B (es) | Uso de ácido (r)-2-[3-[[n-(benzoxazol-2-il)-n-3-(4-metoxifenoxi)propil]aminometil]fenoxi]butírico o una sal, o solvato del mismo para el tratamiento de la esteatosis hepática no alcohólica, supresión de la deposición de grasa en el hígado, y en la reducción de células de kupffer en el hígado. | |
| CL2013002341A1 (es) | Compuestos derivados de 6-ciclobutil-1,5-dihidro-pirazolo [3,4 d]pirimidin-4-ona, inhibidores de pde9a; composicion farmaceutica; y su uso para el tratamiento de una enfermedad o afección relacionado con deterioro cognitivo, enfermedad de alzheimer, demencia vascular, entre otros | |
| IL228906A0 (en) | Quinazoline derivatives for the treatment of viral infections and further diseases | |
| PE20140255A1 (es) | Tableta dispersable en forma oral | |
| UY33863A (es) | Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer | |
| EP4578509A3 (en) | Treating elevated levels of eosinophils and/or basophils | |
| BR112013030554A2 (pt) | forma cristalina de ciclosporina a, métodos de preparação e métodos para uso da mesma | |
| WO2012100043A3 (en) | Controlled release oral pharmaceutical dosage forms comprising mgbg | |
| CL2012002540A1 (es) | Hidrato de hidrocloruro de agomelatina; forma cristalina; metodo de preparacion; composicion farmaceutica ; y su uso para el tratamiento de trastornos del sueño, estrés, ansiedad, depresion mayor, enfermedades cardiovasculares, entre otras. | |
| CL2014000050A1 (es) | Composicion farmaceutica en forma de solucion que comprende apomorfina, un codisolvente micible en agua, un antioxidante y agua, en la que el ph es superior a 4; procedimiento para fabricarla; y su uso como solucion inyectable en el tratamiento de la enfermedad de parkinson. | |
| PE20160012A1 (es) | Tratamiento de enfermedades miopaticas y neurogenerativas por agregacion de proteina mediante administracion parenteral | |
| ITTO20110634A1 (it) | Metodo per trattare patologie organiche del sistema nervoso, la sindrome psicoorganica e l'encefalopatia | |
| IL220318A (en) | Aqueous solutions comprising 3-quinuclidinones for the treatment of hyperproliferative, autoimmune and heart diseases | |
| WO2014164285A3 (en) | Use of levocetirizine and montelukast in the treatment of vasculitis | |
| EA201992832A1 (ru) | Подкожное введение adamts13 | |
| EP2726169A4 (en) | FILTER HEAD, FILTER ARRANGEMENT AND WASTE TREATMENT DEVICE THEREFOR | |
| WO2014153385A3 (en) | Methods of treating metabolic disorders | |
| EP2601967A4 (en) | MEDICINE FOR PREVENTING AND TREATING HIV-RELATED OR HIV-RELATED DISEASES, INCLUDING AIDS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |